Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Tom Brady's playful rivalry with Eli Manning reignited after a viral video showed Brady joking about never losing to Manning, referencing their Super Bowl clashes. Giants fans swiftly responded ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

And Lilly just took a major step in the right direction. Did Eli Lilly just say checkmate to Novo Nordisk? Let's find out. So, first a quick bit about how this class of drugs works. Novo Nordisk's ...

Eli Lilly (LLY) stock surges after positive results about its weight-loss pill trial. Taiwan Semiconductor Manufacturing Company (TSM) stock is in focus after the company reported earnings and ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity ...

Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes management results when compared to the pill’s injectable counterparts. About 1 in 8 adults in the U.S. has taken ...

The India launch of Eli Lilly’s popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about ...

Meanwhile, pharma company Eli Lilly (NYSE: LLY) offers a much lower yield of less than 1%, but its dividend growth rate has been far more impressive. Which stock is the better buy if your priority ...